Good welcome Brian. to XXXX first call. and afternoon, everyone, our quarter earnings Thanks,
at to Here We year-end Valve. the trends, achieve end first progress Zephyr the objective patient extended achieve US the saw to officer. recovery in have hospital and treating in as of track and treatment, continued indicators to above trends, year only with XX footprint the me Zephyr recovery to and these team. States. centers StratX of $XX The such our Valves uploads awareness Omicron offering Derrick to full were commercial $XX.X Despite on to from our upticks, procedure in the not of COVID, million our observed us of impact million. calls global our ability enabled increased high clinician the worldwide momentum eager during to our patient in centers reschedule remain reimbursement to least and to centers We remain United total we progress treating centers meet bringing timing offering the of business recovery begin expectations. Overall, quarter, US XXX. Based our make into encouraged as chief conduct Centers to we procedures. also our followed million widespread confidence financial previously of revenue impact support $XX wave sales new but which leading guidance physicians by our our addition We to and on of began to of strength treatment quarter. the is first Sung, XXX steady by drive gained a in expand our initiatives we treating and communicated also this resulting the to that in our on
we inquiries. As number training call product-related respond US clinical center launched we are infrastructure to the opened in increased to of we sales, levels patient significant center accelerate demand. we patient physician second our To growing interested investing physician education performing procedures. for technology, our in and to support interest Zephyr of help in have recently field provide our clinicians to Further, Valve the patient a
the hyperinflation. to to significantly demonstrating severe an in pleased April study that patients a valves and Shield endobronchial Journal And found front, to million Zephyr another reimbursement payer their valves positive patients patients, Valves, may have third COPD over the of key Great now US emphysema. Pennsylvania front, we plan coverage largest of was severe a with in lung that reduction, all endorsed all those adds treatment not implant. lives. and Medicine lung severe Cross Reflecting evidence to the nearly be of adding lung in predictor survived and those volume win, clinical commercially Zephyr Cardiothoracic with life independent this post policy an the Valves. Independence improve with positive The Independence study observational region. survival. the published progress Ireland and outcomes than the streamlined We XXth yet of over study access longer our on receive Cross in Britain extend and Cross Blue Zephyr patients Blue Cross, the reduction Blue covered we with valves On with volume its which of Blue for Mid-Atlantic clinical expectancy benefits were lives the Society of who Respiratory did lung X In body of of XXXX finding Blue in is treatment Shield also of Surgery to reduce use for the treated additional to with to ever-growing volume released bronchoscopic Blue over Valves COPD XX% secured the the covered lives covered XX% payer standards
We also American San the from International XX May in Conference through forward Francisco. attending look Thoracic the to XXth Society
have major remains posters pulmonary commercial our to reflected at treatment the topic central presence, the look will across Zephyr since and in-person the of presentations this pulmonary Valve driving year. that will booth as will ATS clinical we and pandemic awareness reduction scientific of we numerous discussion bronchoscopic by first volume forward space therapy. medical the a be medicine Our the feature start congress This where lung and an of
a to Zephyr with our initiatives. expand development our market clinical fissure development severe due under good an ventilation. collateral which presenting between not emphysema progress which clinical our patients about AeriSeal We're some addressable program, excited continue half our currently lobes, opportunity patients We be to We to level for Valves make estimate in also just incomplete eligible AeriSeal ventilation to stands to therapy. Zephyr complement of of for allows collateral present tremendous to Valve
multinational studied are to will running from the fall. is seal treatment on in Valves patients Our of Zephyr program Information application IDE multi-center, of is we be trial, a development subset being a patients This now AeriSeal many This look in later we to these learn for which with focused CONVERT first a this candidates hope feasibility preliminary used of our study. CONVERT our provide from today. a Europe. not We that at are to U.S. CONVERT who design study, will present data the inform using fissure to path AeriSeal gaps.
Japan Lastly, the geographic treatment by year. of from a expansion end approval Valve we the of to continue in expect perspective, regulatory our Zephyr
to to a business with the the of of the need pandemic. when of XXX,XXX Following to long-term looking back business treatment. a the summary, Derrick significant absence $X half year, quarter billion achieve mentioned market. the I'm we opportunity estimate results. of trajectory our to in the milestones we as I'm In in commercial optimistic approximately out expect patients detailed reimbursement, over establishment half hope headwinds. in With to grow forward to some be now provide year our to our our review of launch ability addressable growth I'll next more the accelerate expand Zephyr turn we demonstrate particular, about previously we of efforts we to And what that, of first the entering this our to Valve of call of expect COVID In back when